SCHEMBL31501710

SCHEMBL31501710

Fc1cccc(CCc2ccc3ncnc(N4CC5(CCNCC5)C4)c3c2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 3/20 0.41
▸ KIT P10721 1/20 0.40
▸ USP2 O75604 4/20 0.40
▸ CYP2D6 P10635 3/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ CYP1A2 P05177 9/20 0.39
▸ CYP3A4 P08684 9/20 0.39
▸ CLK4 Q9HAZ1 7/20 0.39
▸ CYP2C19 P33261 5/20 0.39
▸ HSD17B10 Q99714 4/20 0.39
▸ KDM4E B2RXH2 3/20 0.38
▸ HPGD P15428 3/20 0.38
▸ LMNA P02545 2/20 0.38
▸ SLC6A2 P23975 2/20 0.38
▸ SLC6A4 P31645 2/20 0.38
▸ SLC6A3 Q01959 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ ALDH1A1 P00352 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31501706 0.91 HTT (0.43) HTTKITUSP2CYP2D6CYP1A2
SCHEMBL31501711 0.89 HTT (0.44) HTTKITUSP2CYP2D6CYP1A2
SCHEMBL25227852 0.89 HTT (0.44) HTTKITUSP2CYP2D6CYP1A2
SCHEMBL31027439 0.85 CYP1A2 (0.51) HTTUSP2CYP2D6ALOX15CYP1A2
SCHEMBL25276551 0.85 CYP1A2 (0.51) HTTUSP2CYP2D6ALOX15CYP1A2
SCHEMBL31501681 0.85 CYP1A2 (0.51) HTTUSP2CYP2D6ALOX15CYP1A2
SCHEMBL25268625 0.84 CYP2D6 (0.46) HTTUSP2CYP2D6CYP1A2CYP3A4
SCHEMBL31501707 0.84 CYP2D6 (0.46) HTTUSP2CYP2D6CYP1A2CYP3A4
SCHEMBL31501685 0.82 CYP1A2 (0.48) HTTKITUSP2CYP2D6CYP1A2
SCHEMBL31501696 0.82 CYP3A4 (0.48) HTTKITUSP2CYP2D6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066358-A1 Inhibitors of Menin-MLL Interaction BALA THERAPEUTICS, INC. 2025-02-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066358-A1 Inhibitors of Menin-MLL Interaction MLLT1, MEN1, BMI1 HTT 3578/4885KIT 1067/4885USP2 3662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback